On the stock market since 2015, it operates in the world of money and finance. Now — the numbers.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The stock trades 29% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 58% — still a thick cushion, though costs have been eating into it lately.
It pays out $0.75 per share each year — regular cash for whoever holds the stock.
The weight of investors positioned for a fall can be felt in the market.
On our five-subject report card, AMIVF sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AMIVF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.